FindTrial
Sign In

Functional Neuroimaging in depression: longitudinal study of PET metabolism in correlation with changes in attentional bias, autobiographical memory, future fluency and facial recognition in depressed patients treated with escitalopram

Functional Neuroimaging in depression: longitudinal study of PET metabolism in correlation with changes in attentional bias, autobiographical memory, future fluency and facial recognition in depressed patients treated with escitalopram

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-005739-91-BE
Enrollment
40
Registered
2006-05-24
Start date
2006-06-21
Completion date
Unknown
Last updated
2014-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depression

Interventions

Product Name: Sipralexa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Escitalopram oxalate CAS Number: 219861-08-2 Concentration unit: mg milligram(s) Concentration type: equal Concentr

Sponsors

University Hospital Ghent
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Major Depression, Depressive episode, following DSM-IV criteria (SCID-I) MADRS-score > 25 Inpatients (at inclusion) and outpatients Age: 18-65 yrs Medication-free or Anti-depressant wash-out 7 days (fluoxetine 6 weeks) Lorazepam 1mg or zolpidem 10mg are allowed Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Bipolar disorder, following DSM-IV criteria (SCID-I) Personality disorder, following DSM-IV criteria (SCID-II) Diabetes mellitus Women without anticonceptive protection, pregnancy or breast feeding Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion Psychotic symptomsSubstance abuse IQ below 80 Cognitive dysfunction due to trauma capitis or dementia

Design outcomes

Primary

MeasureTime frame
Main Objective: To explore alterations in brain metabolism by means of 18F-FDG PET in relation to information processing ratings, in patients with major depression treated with 8 wks escitalopram;Secondary Objective: To explore cross-sectional differences in brain metabolism of depressed patients compared to healthy volunteers (normal database) before and after treatment with escitalopram To explore the influence of 2 and 8 wks escitalopram treatment on information processing (attentional bias, autobiographical memory, future fluency, facial recognition) in patients with major depression To explore the influence of 2 and 8 weeks escitalopram treatment on depression, anxiety and hopelessness ratings in patients with major depression ;Primary end point(s): To evaluate the effect of the antidepressant escitalopram on cognitive functions and brain metabolism in depressed patients.—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026